DE602005015733D1 - Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration - Google Patents

Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration

Info

Publication number
DE602005015733D1
DE602005015733D1 DE602005015733T DE602005015733T DE602005015733D1 DE 602005015733 D1 DE602005015733 D1 DE 602005015733D1 DE 602005015733 T DE602005015733 T DE 602005015733T DE 602005015733 T DE602005015733 T DE 602005015733T DE 602005015733 D1 DE602005015733 D1 DE 602005015733D1
Authority
DE
Germany
Prior art keywords
gpi
chemokine
cells
tissue regeneration
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005015733T
Other languages
English (en)
Inventor
Ralf Prof Dr Huss
Peter Prof Dr Nelson
Hermann-Josef Prof Dr Groene
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apceth GmbH and Co KG
Original Assignee
Apceth GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth GmbH and Co KG filed Critical Apceth GmbH and Co KG
Publication of DE602005015733D1 publication Critical patent/DE602005015733D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602005015733T 2005-12-02 2005-12-02 Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration Active DE602005015733D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05026397A EP1792914B1 (de) 2005-12-02 2005-12-02 Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration

Publications (1)

Publication Number Publication Date
DE602005015733D1 true DE602005015733D1 (de) 2009-09-10

Family

ID=36047948

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015733T Active DE602005015733D1 (de) 2005-12-02 2005-12-02 Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration

Country Status (7)

Country Link
US (1) US20120208769A1 (de)
EP (1) EP1792914B1 (de)
AT (1) ATE437889T1 (de)
AU (1) AU2006319440B2 (de)
CA (1) CA2631587C (de)
DE (1) DE602005015733D1 (de)
WO (1) WO2007062844A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014382A2 (en) * 2007-07-23 2009-01-29 Postech Academy-Industry Foundation Cxcl11 adjuvant compositions and uses thereof
CN101654679B (zh) * 2009-04-16 2012-06-13 浙江省台州医院 一种抗肿瘤融合基因及其表达蛋白与应用
CN102221608A (zh) * 2011-04-06 2011-10-19 浙江大学医学院附属第一医院 一种抗体组合物及其应用
DK2859015T3 (en) * 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
WO2016077249A1 (en) * 2014-11-10 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for expressing polypeptides on the surface of cells
CA2988086C (en) 2015-06-03 2023-09-19 The Medical College Of Wisconsin, Inc. An engineered ccl20 locked dimer polypeptide
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
WO2020146857A1 (en) * 2019-01-11 2020-07-16 Arbele Limited Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof
WO2021087839A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤特异性多肽序列及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
EP1427426A4 (de) * 2001-08-27 2005-05-11 Greenville Hospital System Gpi-verankerte zytokine
CA2625619A1 (en) * 2005-10-14 2007-04-26 Medimmune, Inc. Cell display of antibody libraries

Also Published As

Publication number Publication date
AU2006319440A1 (en) 2007-06-07
ATE437889T1 (de) 2009-08-15
US20120208769A1 (en) 2012-08-16
AU2006319440B2 (en) 2012-02-09
WO2007062844A1 (en) 2007-06-07
CA2631587A1 (en) 2007-06-07
CA2631587C (en) 2013-01-15
EP1792914B1 (de) 2009-07-29
EP1792914A1 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
DE602005015733D1 (de) Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration
Chandrasekaran et al. Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy
EP3414260B1 (de) Zusammensetzungstherapie einschliesslich ein inflamatorisches immumozytokin und ein chimärartiges antigenrezeptor (car)-t-zell
BR112018067379A2 (pt) conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.
JP2018522055A5 (de)
CY1109931T1 (el) Αναστολεις ομοιαζουσας με αγγειοποιητινη πρωτεϊνης 4, και η χρηση τους
HRP20240362T1 (hr) Pripravci i postupci namijenjeni liječenju hematološkog raka, koji ciljaju na međudjelovanje između sirp-alfa i cd47
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
GT200600517A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
TN2015000177A1 (en) Anti-ceacam5 antibodies and uses thereof
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
FR2919804B1 (fr) Composition et vaccin therapeutique anti-tumoral
BR112012009973A2 (pt) promotor de regeneração de tecido usando recrutamento de células-tronco mesenquimais da medula óssea e/ou células-tronco pluripotentes em sangue
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
CY1115774T1 (el) Υπερδιακλαδισμενα πολυανθρακικα για την διαλυτοποιηση δυσδιαλυτων δραστικων ουσιων
MA38477B1 (fr) Mutéines d'interleukine 2 pour la propagation de lymphocytes t régulateurs
AR103714A1 (es) Proteínas específicas para pioverdina y pioquelina
UY33034A (es) Materiales y métodos para el tratamiento o prevención de enfermedades asociadas al her-3
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
PE20200602A1 (es) Compuesto macrociclico y sus usos
PE20081841A1 (es) Composiciones farmaceuticas con capacidad de induccion de apotosis en celulas tumorales, utiles para el diagnostico y tratamiento de la leucemia linfocitica cronica b
Levesque et al. Cell adhesion molecules in normal and malignant hematopoiesis: from bench to bedside
Gerds et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation
BR112022006440A2 (pt) Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo
Obajdin et al. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition